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a b s t r a c t
Limited access to Chagas disease diagnosis and treatment is a major obstacle to reaching the 2020 World
Health Organization milestones of delivering care to all infected and ill patients. Colombia has been
identiﬁed as a health system in transition, reporting one of the highest levels of health insurance
coverage in Latin America. We explore if and how this high level of coverage extends to those with
Chagas disease, a traditionally marginalised population. Using a mixed methods approach, we calculate
coverage for screening, diagnosis and treatment of Chagas. We then identify supply-side constraints both
quantitatively and qualitatively. A review of ofﬁcial registries of tests and treatments for Chagas disease
delivered between 2008 and 2014 is compared to estimates of infected people. Using the Flagship
Framework, we explore barriers limiting access to care. Screening coverage is estimated at 1.2% of the
population at risk. Aetiological treatment with either benznidazol or nifurtimox covered 0.3e0.4% of the
infected population. Barriers to accessing screening, diagnosis and treatment are identiﬁed for each of
the Flagship Framework's ﬁve dimensions of interest: ﬁnancing, payment, regulation, organization and
persuasion. The main challenges identiﬁed were: a lack of clarity in terms of ﬁnancial responsibilities in a
segmented health system, claims of limited resources for undertaking activities particularly in primary
care, non-inclusion of conﬁrmatory test(s) in the basic package of diagnosis and care, poor logistics in the
distribution and supply chain of medicines, and lack of awareness of medical personnel. Very low
screening coverage emerges as a key obstacle hindering access to care for Chagas disease. Findings
suggest serious shortcomings in this health system for Chagas disease, despite the success of universal
health insurance scale-up in Colombia. Whether these shortcomings exist in relation to other neglected
tropical diseases needs investigating. We identify opportunities for improvement that can inform
additional planned health reforms.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Approximately 5.7 million individuals are infected with Trypa-
nosoma cruzidthe aetiologic agent of Chagas diseasedacross the
twenty one Latin American countries where the disease is endemic
(World Health Organization, 2015). Chagas disease is a leading
cause of cardiomyopathy and responsible for considerable social
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and economic hardship. It has been estimated that, on average, an
infected individual incurs US$474 in health-care costs annually and
$3456 across their lifetime (Lee et al., 2013). Precarious access to
care and difﬁculties in the supply of diagnosis and treatment for
thosewith Chagas disease have been reported, in both endemic and
non-endemic countries, as the main obstacles for reaching the
World Health Organization (WHO) and London Declaration goals of
having all infected and ill patients receiving care by 2020 (Tarleton
et al., 2014).
Chagas disease is caused by infection with the parasite T. cruzi,
which is usually transmitted by a triatomine insect vector. The
infection can also be transmitted by blood transfusion, organ
transplantation, and via congenital and oral routes. The disease has
an initial acute stage, which is usually asymptomatic. However, in a
small proportion of cases, this stage can cause severe symptoms. A
chronic phase ensues, which is asymptomatic for the majority of
those with the infection. However, approximately 30e40% of
infected people progress, from a few years to decades after the
initial infection, to a chronic, clinically active phase of the disease,
involving potentially fatal cardiac or gastrointestinal complications
(Rassi and Marin-Neto, 2010; Cucunuba et al., 2016). Public health
interventions for Chagas disease in Latin America have focused on
interruption of transmission by blood-bank screening and vector
control (mainly through insecticide spraying, but also in some cases
by housing improvement, health education, and social changes
such as migration and modernization) (World Health Organization,
2010). These strategies have shown success in decreasing incidence
and burden of disease over time (Hashimoto and Schoﬁeld, 2012;
Schoﬁeld et al., 2006). A reduction by approximately 90% in the
prevalence (from 10% to <1%) in children in endemic areas over the
last four decades in the Southern Cone countries (Dias, 2007) has
led to the goal of interrupting domiciliary transmission in endemic
countries (World Health Organization, 2012). These initiatives have
not, however, been designed to provide care (diagnosis and treat-
ment) to people already infected. Even if interruption of trans-
mission were achievable, given the chronic course of the disease,
people already infected need a responsive health system to meet
their health care needs (Manne et al., 2012).
Diagnosis and treatment of Chagas disease is not an easy task.
Diagnosis requires conducting at least two different serological
tests, which makes it logistically and ﬁnancially challenging. To
date, there are only two drugs available as aetiological treatment:
benznidazol and nifurtimox. Both have proven to be more efﬁca-
cious in early stages and both are associated with frequently re-
ported side effects (Villar et al., 2014). A large clinical trial recently
tested the efﬁcacy of benznidazole amongst adults and found an
inconclusive effect when heart complications were already estab-
lished (Morillo et al., 2015), which suggests there is still debate
about the impact of such etiological treatments as the disease
progresses. Nevertheless, there is consensus on the need to offer
these aetiological treatments to patients, particularly in early stages
and that symptomatic treatment, (such as heart failure and anti-
arrhythmic drugs, pacemakers and transplants) becomes para-
mount for advanced stages (Carlos Pinto Dias et al., 2015).
This analysis focuses on the epidemiological and health system
status of Colombia, where epidemiological data suggest that
approximately 437,960 people are infected with T. cruzi, 30% of
whom have already developed the chronic cardiac form of Chagas
disease (World Health Organization, 2015). Blood-bank screening
in Colombia was declared mandatory in 1995, and since 2003 it has
achieved 100% coverage. However, it was not until 2008 that the
Ministry of Health set up a national programme aimed at control-
ling, preventing and treating Chagas disease (Appendix A, Figure A1
depicts a summary timeline of policy changes). To date, there has
been no assessment of whether, and how, these recommended
diagnostic and treatment pathways, introduced in 2011 (Ministerio
de Proteccion Social, 2011), have been incorporated into the health
systemwhichmakes it difﬁcult for policy makers tomake informed
decisions on resource allocation and improvement of services.
1.1. Overview of health system structure in Colombia
The Colombian health system has been considered a highly
successful example of a health insurance-regulated market
(Giedion and Uribe, 2009; Lewandowski et al., 2015), with positive
effects in terms of health status, ﬁnancial protection and health care
utilisation (Vargas-Zea et al., 2012). A compulsory health insurance
system, known as Law 100, was established in 1993, consisting of
two main sub-systems, namely, the contributory regime for formal
workers and their families, and the subsidised regime for the
population outside the formal economy (Londo~no et al., 1997).
These regimes are administered by private and a few public in-
surers known as Empresas Promotoras de Salud (EPS)dHealth
Promotion Enterprises, which are responsible for organising the
registration of people in the system and delivering health services
through a variety of public and private health care providers
(Vargas et al., 2010). Health service delivery is organised across
three levels: primary care (basic care attended by general physi-
cians and nurses), secondary care (intermediate care with some
specialised physicians, procedures and laboratory), and tertiary
care (the most complex procedures and specialisations) (Castillo-
Riquelme et al., 2008). According to ofﬁcial sources, the insurance
coverage of the health system in Colombia has gradually increased,
reaching near 96% of the population, one of the highest coverage
rates in Latin America (Vargas et al., 2010). Out-of-pocket expen-
diture for health represents 17% of the total health expenditure, one
of the lowest in the Latin American region (Atun et al., 2015; WHO,
2014). Although access to health care in Colombia has increased in
line with insurance coverage, important inequities have been
revealed not only between the two insurance regimes but also
between geographical areas, urban and rural populations, social
strata and ethnic groups (Garcia-Subirats et al., 2014). Activities
that do not involve primary health facilities (such as vector control,
mass screening, and health education) are the responsibility of
governmental institutions (departmental andmunicipal secretaries
of health) and funded from general taxation, usually without
involvement of health insurers (Appendix A, Table A1), which leads
to fragmentation in the delivery of these services.
Given the increasing global health interest in universal health
coverage (UHC), and the noted success of Colombia's move towards
UHC, we use a mixed methods approach to understand how such a
policy initiative translates into practice. Speciﬁcally we explore
how the health system serves those suffering from Chagas disease,
a traditionally marginalised population group. We (i) estimate the
actual coverage of screening, diagnosis and treatment between
2008 and 2014, (ii) identify pathways to provision of services, (iii)
highlight supply-side barriers to accessing services for diagnosis
and aetiological treatment, and (iv) suggest recommendations for
improvement that can inform additional planned health reforms.
2. Data and methods
Access can be deﬁned in terms of two separate components: a)
physical availability, measured as the distribution of available inputs
compared to the appropriate population denominator; and b)
effective availability, measured by how easy it actually is for this
population to obtain care (Frost and Reich, 2008). We have assessed
the former (quantifying the supply of diagnosis and aetiological
treatment using a quantitative approach) and investigated supply-
side barriers associated with the latter (using a qualitative
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approach).
Data collection from the national, departmental and municipal
levels took place in Colombia between January and July 2015 across
the three most Chagas disease endemic regions in Colombia (Boy-
aca, Casanare and Santander) as well as the capital city Bogota.
Fig. 1 gives a schematic representation of the different methods
used to address the study objectives and Figure A2 shows the
locations.
2.1. Quantitative approach for estimating coverage of diagnosis and
treatment
2.1.1. Data sources
Comprehensive records of diagnosis and treatment coverage
were unavailable. Therefore, an extensive document review of data
for supply of diagnostics and therapeutics was performed. This
involved collating the records of purchases and delivery of supplies
for diagnosis and treatment of Chagas disease between 2008 (the
ofﬁcial start of the national programme) and 2014. The review was
conducted ﬁrstly at the national level and subsequently at
departmental level (the political-administrative units in Colombia)
in the three most endemic regions (For details see Appendix A, Box
1).
2.1.2. Data analysis
Coverage (measured as the physical availability and delivery of
diagnosis and treatment) was calculated by comparing the regis-
tered number of screening tests (ﬁrst test), conﬁrmatory tests
(second test(s)) delivered, and treatments allocated, against the
most recent estimates of Chagas disease prevalence in Colombia by
the WHO (World Health Organization, 2015). The total numbers of
screening tests, conﬁrmatory diagnostic tests and allocation of
aetiological treatments were measured and their annual average
calculated. Details about our working deﬁnition of coverage are
discussed further in Appendix A, Box 2.
2.2. Qualitative approach used to explore care pathways and
barriers to access
2.2.1. Data sources
We used a semi-structured questionnaire to explore care path-
ways and barriers for accessing diagnosis and treatment for Chagas
disease. Interviews were conducted with key informants at
different administrative levels of government, hospitals, research
centres, NGOs, and the Pan American Health Organization (PAHO)
(Table 1). Participants were sampled purposefully to ensure in-
terviews captured insight from national, departmental and
municipal levels of those responsible for the provision of Chagas
care either directly or indirectly. In addition interviewees were
asked to nominate other people with speciﬁc experience on the
topic. Two local interviewers, previously trained on the interview
guidelines and unknown to interviewees conducted, audio-
recorded, transcribed, coded and compared the data.
Lastly a group of 30 people (patients, providers, EPS represen-
tatives and policymakers) were invited to participate in a struc-
tured two-day workshop called “Barriers to Accessing Care for
Chagas Disease in Colombia”, where the ﬁndings of both the
coverage calculations and interviews were presented and dis-
cussed. This workshop divided participants into three distinct
discussion groups: i) patients, ii) providers, and iii) insurers. Each
group reﬂected on speciﬁc experiences in the processes of diag-
nosis and treatment and perceived barriers to access from their
group's perspective. A facilitator directed each session and an in-
dependent rapporteur took notes during the discussions. These
discussions were collated into a round-table summary, which was
then presented back to workshop participants and additional
Fig. 1. Summary of aims, research questions, data collection and analysis methods.
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comments were invited from the plenary group. The details of this
workshop can be consulted online (DNDi., 2015).
2.2.2. Data analysis
An analysis was conducted to map the ﬂow of patients through
the health system and identify the various pathways for the pro-
vision of care. This mapping exercise was undertaken to go beyond
the rhetoric of the 2011 clinical guidelines for diagnosis and
treatment of Chagas disease (Ministerio de Proteccion Social, 2011),
and reﬂect the health system realities and complexities reported
during the interviews and workshop.
To better understand barriers to access we used a theoretical
framework known as The Flagship Framework (Reich and Roberts,
2011). It is a macro-policy model that has evolved over the years
and incorporates ethical, political, and policy cycle analyses (Reich
and Roberts, 2011; Shakarishvili et al., 2011). The framework con-
siders a set of “control knobs” or dimensions of a health system
which policy-makers can use to achieve health system goals: (1)
the ﬁnancing domain refers to howmoney is raised and distributed
among different services; (2) the payment domain refers to how the
institutions or providers are paid/reimbursed and the incentives
that this generates; (3) the regulation domain explores the set of
rules for providing care between the different sectors; (4) the or-
ganization domain has to dowith how the activities are delivered in
the ﬁeld, and ﬁnally; (5) the persuasion domain assesses the
awareness of different actors in relation to their role in the system
(Roberts and Reich, 2002). The basic assumption is that modiﬁca-
tions to these dimensions will impact the intermediate objectives
of access, quality, efﬁciency, cost, and equity in ﬁnancing.
Our data were organised into two categories of interest (diag-
nosis and treatment) and then into a high level thematic structure
based on the ﬁve ‘control knobs’ or dimensions. This framework has
been used to contextualise access to care for Chagas disease in
Mexico and the United States of America (USA), permitting inter-
national comparisons (Manne et al., 2013; Manne-Goehler et al.,
2015).
3. Findings
Twelve different datasets containing data for the period
2008e2014 informed the quantitative analyses. These data
included the registries for screening and conﬁrmatory tests as well
as the distribution of therapeutics at national level, which were
cross referenced with registries in the three speciﬁc departments
under closer scrutiny (Boyaca, Casanare and Santander). For the
qualitative analyses, 31 interviews were recorded and examined
across 16 institutions from all levels of the health system. In-
terviews lasted between 30 and 90 min. Characteristics of the in-
terviewees are presented in Table 1.
3.1. Estimating coverage of diagnosis and treatment
3.1.1. Coverage of screening and conﬁrmatory tests
Based on data from the blood bank national reports, a total of
5,094,417 tests were undertaken for screening of Chagas disease
between 2008 and 2014, representing 100% coverage of screening
in donors for this period. By contrast and for the same period, only
54,605 tests were performed across school-age children, adults and
hospital-based screening. The departments of Boyaca, Casanare and
Santander accounted for 85% of these screening tests. Considering
that the current WHO estimate of the number of people at risk of
Chagas disease infection in Colombia is 4,813,543, the coverage of
screening is 1.2%. Hospitals, via insurance funds, deployed the
lowest level of screening activities (4%) (Table 2).
There was no information on conﬁrmatory tests before 2012.
Since then, the number of registered people who undertook a
conﬁrmatory test compared to the total number of people with a
positive ﬁrst test was 82% (789/964) in 2012, 60% (585/973) in 2013,
and 62% (588/953) in 2014. Using an average of 68% of conﬁrmatory
test coverage out of the total number of screened positive cases, we
estimated that between 2008 and 2014, the total number of
conﬁrmed cases in Colombia was 3714 out of the 5470 screened
positive cases (For details, see Appendix A, Table A2).
3.1.2. Coverage of aetiological treatment
Based on national data, the number of aetiological treatment
courses released from the Ministry of Health to the departments
between 2008 and 2014 was estimated to be just enough to treat
3537 cases of Chagas disease, 0.8% of the 437,960 people who are
infected according to WHO estimates (World Health Organization,
2015).
When the individual registries for actual treatments allocated
from the departmental level to the hospitals were reviewed in the
three most endemic departments, it was found that the annual
actual allocation to hospitals varied between 11% and 44% of the
conﬁrmed cases at this level (Appendix A, Table A2). Overall, it was
estimated that among the 3537 conﬁrmed cases, between 1107 and
1641 cases actually received aetiological treatment in the country
between 2008 and 2014 (Appendix A, Table A3 and A4). This ﬁgure
represents an aetiological treatment coverage between 0.3% and
0.4% of the total expected 437,960 cases in Colombia, according to
WHO estimates (World Health Organization, 2015) (Fig. 2).
3.2. Diagnosis and treatment pathways
According to the 2011 clinical guidelines (Ministerio de
Proteccion Social, 2011), a patient should pass through a series of
stages that involve screening, conﬁrmation and treatment. How-
ever, when the different key actors involved in these processes
were asked to describe the actual pathway of patients through the
health system we found that these basic three stages include a
Table 1
Characteristics of key informants interviewed.
Type of informant National level Departmental Level (FOAD) Municipal Level (SOAD) Othera Total
Programme directors and coordinators 2 7 2 2 13
MD, general practitioners or Nurses 4 2 8
MD, cardiologists 2 1 2
Technicians 5 5
Microbiologists 2 1 1 4
Total 10 9 10 2 31
FOAD: First order administrative division.
SOAD: Second order administrative division.
MD: medical doctor or physician.
a Non-governmental organizations (NGOs) and Pan American Health Organization (PAHO).
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series of sub-processes that then act as bottlenecks where patients
can spendmonths or even years before effectively continuing to the
next step. Fig. 3 maps the often complex health system pathways
and sub-processes patients are likely to experience.
Five possible sources for screening of Chagas disease in
Colombia were identiﬁed, covering three target populations: blood
donors, active school-age children and hospital-based consulta-
tions (this includes antenatal consultations). Having been screened
positive, to access the conﬁrmatory test, a patient then follows
different routes according to their type of health insurance. Once
conﬁrmed as positive via both tests, the access to aetiological
treatment requires several additional steps and largely depends on
the distribution of drugs from the national to the local level.
3.3. Supply-side barriers to delivering and accessing care
Various stakeholders at different health system levels reﬂected
on the barriers to accessing Chagas diagnosis and treatment. In-
sights are presented, with supporting quotes, organised by the ﬁve
domains identiﬁed in the Flagship Framework and summarized in
Table 3.
3.3.1. Financing domain
Prevention activities for Chagas disease (vector control, educa-
tion and mass screening) are mainly ﬁnanced through general
taxation and delivered by secretaries of public health through
schools or households. However, individual health care services
(doctor appointments, treatments, procedures in health facilities)
are mainly ﬁnanced either by workers' contributions (contributive
regime) or governmental subsidies (subsidised regime) that are
paid to insurance companies and then delivered through public or
private health facilities.
There was general consensus amongst stakeholders that this
segmentation of the health system led to a lack of clarity about the
speciﬁc responsibilities between public institutions (Departmental
Secretaries of Health) and health insurers for ensuring the delivery
of Chagas care.
Opinions differed across respondents on how the insurance type
(contributive vs. subsidised) affected access. At the national level,
there was mainly a perception that the two regimes were moving
towards providing equal entitlement. However, most of those
interviewed at departmental and municipal levels reported that
patients in the subsidised regime experienced more difﬁculties
obtaining diagnostic resources, particularly conﬁrmatory tests:
“In the last ﬁve years we have identiﬁed about 200 suspected cases,
patients who are positive to the ﬁrst test, mostly from the sub-
sidised regime. But, as the insurance company has not authorised
the second tests, these cases have not been conﬁrmed … “(Coor-
dinator, secretary of health at municipal level)
One respondent considered that inequalities in access were due
to both the type of insurance and geographical provenance of the
patients:
“People registered in the contributive regime are mainly located in
cities, whereas people covered by the subsidised regime are mainly
located in rural areas. Most of the health facilities are located in
urban areas and it is in rural areas where the barriers to access are
more concentrated …”(Physician, NGO)
3.3.2. Payment domain
The principal method of payment for health care providers in
primary care is to receive a ﬁxed payment per patient regardless of
the services delivered, also referred to as a capitation payment.
According to the coordinators and directors at primary care level,
this is a major resource constraint, especially when the prevalence
of the disease is high:
“With the same amount we get paid by the insurance companies
we have to deliver the complete package of care for all diseases. The
resources at local level in terms of personnel, equipment, etc. are
not sufﬁcient for attending the special needs of Chagas disease
patients at the primary care level or outside the health facilities”
(Director, primary care level)
All those interviewed agreed that out-of-pocket expenditure
was needed to cover the costs of conﬁrmatory tests and of trans-
portation to attend the several visits to the doctor and receive the
different procedures that are needed:
“Approximately, patients require eight appointments to ﬁnally
receive aetiological treatment, plus the additional follow-up ap-
pointments. And, every time they go to the doctor they need to pay
transportation from their villages to the city and take the day off,
Table 2
Coverage of screening (ﬁrst test) for Chagas disease in Colombia between 2008 and 2014.
Year Screening of population at risk (living in endemic areas or with heart complications) Screening at
blood banks
Active screening in endemic areas Passive screening Total Screening of
population at riskb
NHI Secretaries of health MSF Research centresa Hospitalsc
2008 3149 6292 0 654 No data 10,095 756,018
2009 5044 463 4205 0 310 10,022 692,487
2010 6854 1898 0 900 442 10,094 692,485
2011 3122 3057 2252 803 460 9694 710,825
2012 1782 0 0 0 304 2086 746,059
2013 973 4569 0 0 248 5790 740,173
2014 1728 7297 0 164 256 9445 756,370
Total 22,652 23,576 6457 2521 2020 57,226 5,094,417
Target 4,813,543 5,094,417
Coverage 1.20% 100%
NHI: National Health Institute; MSF: Medecins Sans Frontieres.
a Research centres: CINTROP/UIS, Centro de Investigaciones en Enfermedades Tropicales at Universidad Industrial de Santander, Universidad del Magdalena, Universidad de
Antioquia and Universidad Antonio Nari~no).
b Blood bank screening was not included in this total as it is not aimed at identifying (screening and diagnosis) people in endemic areas but at the prevention of transfusional
transmission.
c Adjusted for under-reporting of 50% in original data sources.
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which means that some patients are not able to afford the whole
process of obtaining a treatment” (Technician at departmental
level)
3.3.3. Regulation domain
Regulation of the health system has implications for both
diagnosis and treatment at different but interconnected levels.
In terms of diagnosis, only one of the two tests needed is
included ofﬁcially on the insurers' list of basic authorised proced-
ures. According to physicians and health professionals interviewed
at local levels, in the majority of cases this necessitates the second
test, a conﬁrmatory test, being authorised as a special procedure by
the insurance company. The exclusion of the conﬁrmatory test in
the standard package of care leads to signiﬁcant delays between
screening and conﬁrmation, and it was identiﬁed as a critical
problem from both care providers and programme managers:
“Sometimes the results after the screening test take months to get
back to us, and the patients come to the hospital looking for the
result and we do not know what to say … sometimes we take
samples of a pregnant woman at the beginning of the pregnancy
and the result ﬁnally gets back to us when the baby has already
been born” (Programme coordinator at municipal level)
Coordinators from the national and department levels reported
that the conﬁrmatory test can also be accessed through a special
request to the departmental secretaries of health. Most of those
interviewed at municipal level, however, suggested that such re-
quests were either slow to process or stock was unavailable.
Therefore, out-of-pocket expenditure was common for accessing
the conﬁrmatory test.
Up until 2011 blood banks - primarily private institutions
designed to prevent infection through transfusion of blood com-
ponents - were not obliged to perform the conﬁrmatory test nor
inform people of their potential infection status. Many infected
individuals were stranded, sometimes for years, unaware of their
status. In response to this, blood banks have had to inform people
about their infection status (since 2011) and conduct a conﬁrma-
tory test and advise patients to seek care (since 2014). According to
national ofﬁcials, this change in policy has not been well received
by blood banks and there are still several problems with its
implementation:
“The administration of the conﬁrmatory test in blood banks is a
great idea, but it means an additional cost for these private in-
stitutions, and it becomes especially costly in endemic areas where
the prevalence [of Chagas disease] in donors is higher” (Coordi-
nator at national level)
With respect to treatment, regulatory challenges extend beyond
the government provision of care to include pharmaceutical regu-
lation. Benznidazole and nifurtimox have been included in the
ofﬁcial list of basic medicines in Colombia since 2011, meaning that
in principle everyone in the country has the right to receive these
treatments if needed free of charge. These medicines are recog-
nised as part of the drugs for special public health programmes
(together with those for malaria, leprosy and tuberculosis, among
others). This implies that, in contrast to other diseases, acquiring,
paying (in the case of Benznidazole) and distributing the drugs is an
Fig. 2. Estimated number of treatments allocated from national level and actually delivered at local level against the number of conﬁrmed cases.
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Fig. 3. Pathways for the provision of diagnosis and treatment for Chagas disease in Colombia.
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exclusive responsibility of the Ministry of Health instead of the
insurance companies.
Coordinators at the Ministry of Health either receive a limited
and sporadic donation of these medicines (as is the case for nifur-
timox, donated by PAHO) or buy the drugs directly through the
Regional Revolving Fund for Strategic Public Health Suppliesda
PAHO mechanism for procurement of strategic public health sup-
plies (Pan American Health Organization, 2006)d(as is the case for
benznidazole). However, as the drugs currently do not have a na-
tional licence, every time a new importation is needed, a very
complex administrative process lasting months, sometimes years,
takes place. As with all pharmaceutical drugs in Colombia, the drug
licensing is regulated by the Colombian National Institute of Drugs
and Food Surveillance (INVIMA) (INVIMA, 2015). The application
for obtaining this licence can only be made by pharmaceutical or
commercial companies, but in the case of Chagas disease, interest
in obtaining these permissions is low as the market is not lucrative.
The only time that benznidazole was registered in Colombia was in
2006 (when it was still produced by Roche). Unfortunately, this
type of permit lasts only for ﬁve years, and for benznidazole it
expired in 2010 (registry 19906435). Similarly, the licence for
nifurtimox (produced by Bayer) expired in 2005 (registry 42704)
(INVIMA, 2015). This is an important barrier that translates into a
very irregular ﬂow of essential medicines into and within the
country.
“We need to ﬁnd a way to get the licensing registry directly by the
Ministry of Health, because the pharmaceutical companies are not
interested in doing all the paperwork for licensing only this very
small amount of medicines we import every year” (Coordinator at
national level)
The situation described by NGOs that have conducted treatment
programmes in Colombia, is in line with the previous viewpoint:
“When we attempted to start our Chagas treatment programme in
Colombia, … we had to address so many obstacles. One of those
was the lengthy approval for the treatment to enter the country, by
which time the treatments had expired because of the adminis-
trative delays from governmental agencies to give clearance for the
procedure. Basically, the Colombian legislation is designed almost
exclusively for proﬁt companies and not for non-proﬁt organisa-
tions such as ours“ (Coordinator, NGO)
At the local level, the perception about treatment availability
was that the drugs were very difﬁcult to obtain and restricted to
special cases.
“It is hard to engage the community in screening campaigns when
we do not have enough treatment to offer. The availability of
treatment is only for acute cases” (Technician at municipal level)
Many of those interviewed referred to how a low number of
tests performed and conﬁrmed, a lack of incentive to import
treatment and a chronic shortage of available treatment, all
contributed to de-incentivise the implementation of the screening
programmes and helped to maintain the status quo:
“I think here about half of the people who attend consultations
might be infected but, as there are not available treatments, we
prefer not to do the test(s) because we do not have anything to offer
to the infected patients” (Physician in endemic area at municipal
level)
3.3.4. Organization domain
In terms of delivering diagnosis, screening of school-age chil-
dren and pregnant women (Cucunuba et al., 2014) is, according to
the Ministry of Health, a shared responsibility between the
municipal secretaries of health, the departmental secretaries of
health and the insurance companies in collaboration with the local
communities. However, ambiguity about institutional roles and
responsibilities hinders effective deployment of screening:
“The municipalities are willing to do schoolchildren screening but
only when the national and departmental levels are actually
pushing them to do it” (Coordinator at departmental level)
“Screening for pregnant women is not mandatory, so it depends
primarily on the interest of the local secretaries of health. Some of
them conduct screening but others simply don't do it” (Coordinator
at national level)
The conﬁrmatory test is usually an Immunoﬂuorescence test,
and requires a more complex laboratory infrastructure and exper-
tise only available in reference laboratories in the capital city of
Table 3
Supply-side barriers to delivering diagnosis and treatment for Chagas disease in Colombia.
Domain Diagnosis Treatment
Financing - Segmented sources of ﬁnancing: service delivery through the insurers
system, and mass screening from taxation
- Annual budget depends on internal advocacy at the Ministry of
Health, at central level
- Nifurtimox is donated by Pan American Health Organization
Payment - Primary care level receives payment through capitation system
- Out-of-pocket expenditures related to transportation for obtaining
authorisations at all levels
- Primary care level receives payment through capitation system
- Out-of-pocket expenditures related to transportation for obtaining
authorisations at all levels
Regulation - Lack of licensing for some diagnostic tests
- Differential access to conﬁrmatory test according to regime
(contributive vs. subsidised)
- Absence of licensing for the current drugs (benznidazole and
nifurtimox)
- National availability of drugs for Chagas disease is highly variable and
irregular within the country, leading to times of excess supply
followed by times of deﬁcient supply
Organization - About 30% of patients who test positive in the initial screening are lost
to follow-up and remain unconﬁrmed due to long delays in obtaining
conﬁrmatory exams.
- Conﬁrmatory test only performed in reference laboratories
- Specially challenging in remote areas and hard-to-reach populations,
i.e. indigenous communities
- Treatment guidelines have not been updated
- Poor logistics at organising medicine stocks at departmental and
municipal levels. Personnel with poor training for treatment activities
- Some supplementary tests need authorisation at the second level of
care
- Delays in appointments and services, particularly for populations in
rural areas
- Specially challenging in remote areas and hard-to-reach populations,
i.e. indigenous communities
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each department. This organisational delay was frequently identi-
ﬁed at the municipal level:
“It would be great if a conﬁrmatory test were available at the
primary care level so the patients could obtain their diagnosis
without delays. At the moment patients have to wait, sometimes
months, for the conﬁrmatory tests or they have to go on their own
to the capital to obtain such a test” (Nurse, municipal level)
In terms of delivering treatment the Ministry of Health dis-
tributes the limited drug supply based on a convoluted process
starting with individual requests from the departmental level
(Fig. 2). All those interviewed commented on this slow process, as
well as on the absence of a stock of treatments at departmental and
municipal levels, leading to excessive delays. Once treatment is
ﬁnally given to the patient, the follow-up procedure includes a
number of supplementary tests needed for monitoring adverse
effects (i.e. evaluation of liver transaminases). Some of these tests
are not part of the primary care level, and hence require an addi-
tional bureaucratic procedure for their authorisation at secondary
level. Such formalities translate into more delays. Delays in ap-
pointments and services are particularly prevalent for rural
populations:
“Some patients make much effort to come to the secretary of health
(at departmental level) and then they are not attended because
they didn't have a speciﬁc previous authorisation from the
municipal level or form from the insurance company. Some people
get tired with all these processes” (Technician at municipal level)
As the drugs for Chagas disease are distributed through the
vector-borne disease programmes, the personnel involved in these
activities are more experienced with vector control activities
(insecticide spraying) thanwith drug administration. This situation
perhaps does not represent a problem for other vector-borne dis-
eases such as malaria, where general knowledge about treatment is
much more extensive, the drugs are easier to administer and there
are fewer adverse effects. For anti-trypanosomal treatment, the
regimens are prolonged (over 60 days) with frequent adverse ef-
fects and a need for regular medical appointments during the
course of treatment:
“In the majority of cases the only person we can have for allocating
the treatments at departmental level is a technician without any
clinical training, who has this as one of many other vector control
activities and does not have either the time or the training for
prioritising or properly distributing a limited amount of drugs.
Additionally, very often [medical] doctors from endemic areas are
not very familiar with the treatments, so they often call us asking
for advice or guidance that on many occasions we cannot offer”
(Coordinator at departmental level)
The lack of standardised treatment guidelines for the physicians
to follow was a commonly reported frustration. The ﬁrst guidelines
for Chagas disease treatment were ofﬁcially published in 2011 and
updated in 2014, but their dissemination has been problematic and
resulted in a low level of implementation.
“The problem with publishing the guidelines is that they must be
published all together with the guidelines for other diseases. So, as
there are delays with some of them, everything is delayed”(Health
ofﬁcer at national level)
Diagnosis and treatment in remote indigenous communities has
been largely conducted by NGOs which has posed additional
challenges:
“Health personnel in indigenous communities are insufﬁcient. They
are in charge of several programmes (tuberculosis, leprosy, vacci-
nation, mother-child care, respiratory and gastrointestinal in-
fections, etc.). Clearly, conducting screening and treatment
programmes for Chagas disease requires additional and trained
personnel” (NGO coordinator)
“In the Sierra Nevada [de Santa Marta] region, there are approxi-
mately 20,000 infected people, but there is not enough treatment
and capacity to treat them all” (NGO coordinator)
3.3.5. Persuasion domain
Lack of knowledge about Chagas disease and the different pro-
cedures needed to deliver treatment among professional health
workers (physicians, nurses, microbiologists and technicians) was a
common concern across all levels. Training workshops have been
conducted in some endemic areas annually since 2000. However,
given that most doctors in rural areas are recent graduates per-
forming their required social service, continuous rotation and staff
turn-over dilutes the impact of training:
“Doctors here are changed every 6e12 months, and sometimes
even faster because they ﬁnd it very difﬁcult to live in these rural
and remote areas. They usually do not know about these tropical
diseases and their treatments” (Director at municipal level)
“Some [medical] doctors sometimes prescribe wrong doses, length
of treatment, or give an inappropriate set of recommendations to
patients about contraindications or other measures to be taken
during treatment. We have received all sorts of enquiries about the
drugs from doctors, and even though we are not doctors ourselves
sometimes we have to correct them” (Coordinator at departmental
level)
Additionally, in some regions, there was a perception among
general practitioners that the treatment had adverse effects that
could only be managed by a specialist (usually a cardiologist or
infectious disease specialist), for which an appointment in
Colombia can take several weeks or months to be approved:
“Sometimes the doctor tells patients that treatment is worse than
the disease, so people get scared of it and prefer not to be treated”
(Technician, departmental level).
Finally, several respondents suggested that funding for vector-
borne diseases is mainly driven by epidemic awareness rather
than by knowledge of the burden of the more chronic NTDs:
“The ﬁnancial resources are insufﬁcient. A media phenomenon
drives investments [for NTDs] at the national level. For example this
year it is only Chikungunya that policy makers care about. There is
a marked inequality between investments for controlling certain
diseases” (Physician, NGO)
4. Discussion
Despite the reported success of universal health insurance in
Colombia and reported high coverage of care in Colombia, our es-
timates suggest coverage and access to diagnosis and treatment for
Chagas disease is strikingly low. Screening coverage is estimated at
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1.2% (57,226 screened out of the 4,813,543 people at risk) and
aetiological treatment coverage at 0.3e0.4% (1107e1631 allocated
treatments out of the estimated 437,960 infected people). While
our estimates have a high degree of uncertainty, these rates are
similar to those reported for Mexico and the USA (Manne et al.,
2013; Manne-Goehler et al., 2015). It is important to notice that
our calculations are based on an estimate of the total number of
infected cases. However, as a proportion of them are in advanced
chronic stage where the aetiological treatment is not indicated, the
potential demand is not necessarily the total number of infected. As
we do not have information about the stage of the people already
treated we are not able to make a more precise estimate on the
projected demand. We can assume, however, that even a more
reﬁned calculationwould show coverage to be within the same low
range.
We estimated that between 60 and 82% of screened positive
cases received a conﬁrmatory test and that, despite delays, aetio-
logical treatment has been delivered to 31e44% of the conﬁrmed
cases. In endemic areas, the greatest challenge for the health sys-
tem is access to a screening test, further compounded by an
irregular supply of treatment.
The provision of diagnosis and treatment of Chagas disease in
Colombia was identiﬁed as a complex pathway of care that com-
bined public and private actors, without clear demarcation of their
responsibilities in the health system. Barriers to access include
substantial problems in the ﬁve dimensions scrutinised here. A lack
of clarity in terms of ﬁnancial responsibilities in a segmented health
system, claims of limited resources for undertaking activities
particularly at the primary care level, non-inclusion of conﬁrmatory
tests in the basic package of care, poor logistics in the distribution
chain of drugs, and lack of knowledge and awareness by medical
personnel were the main health system barriers identiﬁed. These
problems echo the concerns of a recent evaluation of the Colombian
Health Systems calling for improved accessibility and quality of
health care (OECD, 2016).
The Flagship Framework is a pragmatic approach that enables
policymakers and policy analysts to effectively diagnose health
systems' problems and develop solutions that are dynamic and
well-coordinated across the actors of the health system (Reich and
Roberts, 2011). This approach is skewed to the macro-components
of the supply side of the health system and potentially under-
emphasises the demand side and social values (van Olmen et al.,
2012). Other frameworks and approaches provide additional per-
spectives. These include the “Building Blocks Framework” (WHO,
2007), which emphasises such aspects as health workforce, lead-
ership and governance, and the “Social Determinants of Health”
approach, which explicitly recognises that health systems are
themselves social determinants for health and health equity
(Marmot, 2008). However, given our supply-side focus, the limited
sources of information that were available, and the use of the
Flagship Framework to analyse other health systems in the context
of Chagas disease (Manne et al., 2013; Manne-Goehler et al., 2015),
the use of this particular framework was deemed appropriate.
The research is not without limitations. Scarcity of data when
moving from the national to the departmental and municipal levels
posed challenges. At times our estimates had to rely on manual
searches. While these searches were conducted as thoroughly as
feasible, they may have missed important information and led to
underestimates at departmental level. Although we went to great
lengths to identify all potential sources, it is possible that tests
performed by private providers not registered through the health
system have been missed. However, given the health system
structure in Colombia, it is unlikely that these providers play a
signiﬁcant role in either diagnosis or treatment. The focus of our
attention was the range of supply-side challenges associated with
providing services to address Chagas disease care; however, we
recognise the importance of exploring demand-side constraints.
The patients' point of view is essential in understanding treatment-
seeking behavior both within the formal health system and else-
where. Several studies have looked at the patients' perspective and
discussed socio-cultural aspects regarding access to care in
endemic and non-endemic areas (Forsyth, 2015; Ventura-Garcia
et al., 2013).
5. Conclusion
Increasing coverage and improving access to care for Chagas
disease patients involves a complex network of many actors and
institutions. Serious shortcomings exist in the health system for
Chagas disease, despite the reported success of universal health
insurance in Colombia. Speciﬁc recommendations aimed at
improving access to diagnosis and treatment of Chagas disease in
Colombia are listed in Table 4.
The barriers to accessing Chagas diagnosis and treatment in
Colombia echo those that have been found in Mexico and the USA
(Manne et al., 2012) (Manne et al., 2013; Manne-Goehler et al.,
2015). The inclusion of aetiological treatment of Chagas disease is
very recent in all three health systems. Yet despite their differences,
Table 4
Recommendations for improving access and coverage of diagnosis and treatment for Chagas Disease.
Domain Recommendation
Financing  Implement a speciﬁc and regularly updated annual budget to acquire diagnostics and medicines to help implementing large-scale screening
campaigns in endemic areas in general and rural and indigenous areas in particular
 Advocate to national and international donors to make programmes sustainable
 Continue progress towards aligning the different health systems regimes (e.g. contributive and subsidised in Colombia)
Payment  Introduce positive incentives (ﬁnancial or non-ﬁnancial) to encourage the primary care level to provide screening, conﬁrmation and treatment
Regulation  License benznidazole and nifurtimox, possibly in coordination with international agencies (e.g. WHO) and other countries with similar barriers
 Include the entire set of diagnostic tests in the list of basic procedures authorised by the health system at the primary care level
Organization  Document and publish national and subnational milestones for diagnosis and treatment, including clear demarcation of responsibilities for each
actor involved in the provision of screening, conﬁrmation and treatment
 Publish and implement the updated guidelines of diagnosis and treatment
 Implement a special treatment programme at municipal level in high prevalence areas, in which current infrastructure and resources are
insufﬁcient to attend an excess demand of services
 Include mandatory screening test during pregnancy and promptly provide results and access to treatment
 Incorporate the provision of screening and conﬁrmatory test at primary care level. Conﬁrmatory test might be changed from IFAT (which requires
specialised laboratories) to simpler tests (e.g. ELISA using recombinant antigens)
 Provide training at departmental secretaries of health to improve delivery of medicines to local hospitals
 Consider installation of medicine stocks, particularly in highly endemic areas to avoid unnecessary delays
Persuasion  Continue advocacy work with health authorities at all levels so that Chagas disease is on the agenda
 Introduce and regularly deliver training modules on diagnosis and treatment to medical doctors working in endemic areas
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the problems of providing care to patients with Chagas disease are
strikingly similar and stem from both national and transnational
challenges. This suggests that to successfully provide care, a more
coordinated global health response is needed. This response needs
leadership, with commitment from national, regional and inter-
national agencies, to help address barriers such as the timely
issuing of drug import licenses. Lessons may be learned from the
reported successes of addressing other NTDs such as lymphatic
ﬁlariasis, and schistosomiasis (Hotez et al., 2007). Colombia was
declared the ﬁrst country to achieve elimination of Onchocerciasis
(WHO, 2013). To repeat these successes in addressing Chagas dis-
ease will require a ﬁrm commitment from all levels of government
and a coordinated, collaborative global response from international
health organizations and other stakeholders.
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